SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-334425
Filing Date
2021-11-19
Accepted
2021-11-19 06:08:04
Documents
15
Period of Report
2021-11-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d252924d8k.htm   iXBRL 8-K 31649
2 EX-1.1 d252924dex11.htm EX-1.1 179273
3 EX-5.1 d252924dex51.htm EX-5.1 9148
7 GRAPHIC g252924g1119072409350.jpg GRAPHIC 2535
  Complete submission text file 0001193125-21-334425.txt   407958

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA kzr-20211119.xsd EX-101.SCH 2904
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE kzr-20211119_lab.xml EX-101.LAB 18888
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kzr-20211119_pre.xml EX-101.PRE 11869
8 EXTRACTED XBRL INSTANCE DOCUMENT d252924d8k_htm.xml XML 3476
Mailing Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-822-5600
Kezar Life Sciences, Inc. (Filer) CIK: 0001645666 (see all company filings)

IRS No.: 473366145 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38542 | Film No.: 211426330
SIC: 2834 Pharmaceutical Preparations